Antibody reactivity against SARS-CoV-2 in adults from the Vancouver metropolitan area, Canada
Authors:
- Abdelilah MajdoubiAMAbdelilah Majdoubi
- Sarah E. O’connellSOSarah E. O’connell
- Christina MichalskiCMChristina Michalski
- Sarah DadaSDSarah Dada
- Sandeep NarparlaSNSandeep Narparla
- Jean GelinasJGJean Gelinas
- Disha MehtaDMDisha Mehta
- Claire CheungCCClaire Cheung
- Matthias GörgesMatthias Görges
- Vilte E BarakauskasVBVilte E Barakauskas
- David M. GoldfarbDGDavid M. Goldfarb
Preprint
Abstract
Background: Quantifying antibody reactivity against multiple SARS-CoV-2 antigens at the population level may help understand individual differences in COVID-19 severity. Pre-existing low antibody cross-reactivity may be particularly prevalent among childcare providers, including pediatric health care workers (HCW) who may be more exposed to circulating coronaviruses. Methods: Cross-sectional study that included adults in the Vancouver area in British Columbia (BC), Canada, between May 17 and June 19, 2020. SARS-CoV-2 seroprevalence was ascertained by measuring total SARS-CoV-2 IgG/M/A antibodies against a recombinant spike (S1) protein and adjusted for bias due to false-positive and false-negative test results. A novel, high sensitivity multiplex assay was also used to profile IgG against four SARS-CoV-2 antigens, SARS-CoV and four circulating coronaviruses. Findings: Among 276 participants (71% HCW), three showed evidence of direct viral exposure, yielding an adjusted seroprevalence of 0.60% [95%CI 0% – 2.71%], with no difference between HCW and non-HCW, or between paediatric and adult HCW. Among the 273 unexposed individuals, 7.3% [95%CI 4.5% – 11.1%], 48.7 [95%CI 42.7% – 54.8%] and 82.4% [95%CI 77.4% – 86.7%] showed antibody reactivity against SARS-CoV-2 RBD, N or Spike proteins, respectively. SARS-CoV-2 reactivity did not significantly correlate with age, sex, did not significantly differ between HCW and non-HCW (prevalence 1.0% vs 1.0%; P =1.00) and between pediatric and adult HCW (0.7% vs 1.6%; P =0.54), and modestly correlated with reactivity to circulating coronaviruses (Spearman rho range: 0.130 to 0.224 for 7 significant (FDR 5%), out of 16 correlations, from 36 correlations tested). Interpretation: A substantial proportion of individuals showed low, but detectable antibody reactivity against SARS-CoV-2 antigens in this population despite low evidence of direct SARS-CoV-2 exposure. Funding: NIAID/NIHKeywords
This publication has 24 references indexed in Scilit:
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humansScience, 2020
- SARS-CoV-2 seroprevalence in COVID-19 hotspotsThe Lancet, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020medRxiv, 2020
- Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal BetacoronavirusesmedRxiv, 2020
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in MichiganThe Journal of Infectious Diseases, 2020
- Epidemiology, Genetic Recombination, and Pathogenesis of CoronavirusesTrends in Microbiology, 2016
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990